Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-19
    E.g., 2018-11-19

Articles

Pages

13484 items
11:14 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round Nov. 15 to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and...
9:43 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Synthrox proposes $100M IPO ahead of synthetic IL-2 clinical testing

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) proposed to raise $100 million in a NASDAQ IPO, according to an SEC filing from Nov. 13. Synthorx is using synthetic biology to develop a pipeline of Synthorin...
7:59 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering...
7:58 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Opko raises $92.5M in private placement

Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) raised $92.5 million in a private placement on Nov. 8 through the sale of 26.5 million shares at $3.49. The price is a 10% discount to Opko's close of...
7:58 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
7:58 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Nestle invests $98M in Aimmune

The Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) will invest $98 million in Aimmune Therapeutics Inc. (NASDAQ:AIMT) through the purchase of 3.2 million shares at $30.27. The price is a slight discount to Aimmune’s...
7:57 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) proposed to list on the Hong Kong stock exchange...
7:57 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Eton raises $21.6M in IPO

Eton Pharmaceuticals Inc. (NASDAQ:ETON) raised $21.6 million on Nov. 12 in an IPO on NASDAQ through the sale of 3.6 million shares at $6. National Securities Corp., a subsidiary of National Holdings Inc. (NASDAQ:NHLD), was...
7:57 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million on Nov. 11 in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears up to bring two more of...
7:56 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Kleo raises $21M series B to advance to clinic in 2020

Immuno-oncology company Kleo Pharmaceuticals Inc. (New Haven, Conn.) raised $21 million in an untranched series B round on Nov. 13 to propel its next-generation Antibody Recruiting Molecules (ARMs) into the clinic by 2020. The round...

Pages